X

Trial Profile

Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monocloncal Antibody

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 03 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Benralizumab (Primary)
Indications Urticaria
Focus Therapeutic Use

Most Recent Events

01 Mar 2021 Results of an efficacy analysis of Benralizumab (anti-IL5 mAb) in the treatment of Chronic Spontaneous Urticaria and biologic pathways involved presented at the 2021 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
16 Mar 2020 Results presented at the 2020 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
08 Jul 2019 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com